These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21524565)

  • 21. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials.
    Gilbert PB; Luedtke AR
    J Infect Dis; 2018 Sep; 218(suppl_2):S99-S101. PubMed ID: 30247601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Just say no to shingles! The zoster vaccine: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(6):281-3. PubMed ID: 22016014
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies with herpes zoster vaccines in immune compromised patients.
    Levin MJ; Bresnitz E; Popmihajlov Z; Weinberg A; Liaw KL; Willis E; Curtis JR
    Expert Rev Vaccines; 2017 Dec; 16(12):1217-1230. PubMed ID: 29053937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination to prevent herpes zoster and postherpetic neuralgia.
    Oxman MN
    Hum Vaccin; 2007; 3(2):64-8. PubMed ID: 17299270
    [No Abstract]   [Full Text] [Related]  

  • 29. An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability.
    La EM; Trantham L; Kurosky SK; Odom D; Aris E; Hogea C
    Hum Vaccin Immunother; 2018 Feb; 14(2):430-441. PubMed ID: 29194019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates of Protection for Herpes Zoster Vaccine: Evaluating Candidate Immunological Variables.
    Dunning AJ
    J Infect Dis; 2015 Nov; 212(9):1521. PubMed ID: 25985903
    [No Abstract]   [Full Text] [Related]  

  • 31. Varicella virus and the herpes zoster vaccine. A review of Zostavax and the new AFIP recommendations.
    Ebede TL; Zippin JH
    J Drugs Dermatol; 2008 Dec; 7(12):1173-6. PubMed ID: 19137773
    [No Abstract]   [Full Text] [Related]  

  • 32. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M; Keating GM
    Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.
    Oxman MN; Schmader KE
    Clin Infect Dis; 2014 Oct; 59(7):920-2. PubMed ID: 25097080
    [No Abstract]   [Full Text] [Related]  

  • 36. CNS Infections: A new herpes zoster subunit vaccine for older adults.
    Warren-Gash C; Breuer J
    Nat Rev Neurol; 2016 Dec; 12(12):682-683. PubMed ID: 27834395
    [No Abstract]   [Full Text] [Related]  

  • 37. Herpes zoster: The changing landscape.
    Caldera F; Ninos CL; Hayney MS
    J Am Pharm Assoc (2003); 2017; 57(2):281-283. PubMed ID: 28285776
    [No Abstract]   [Full Text] [Related]  

  • 38. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.
    Sly JR; Harris AL
    Nurs Womens Health; 2018 Oct; 22(5):417-422. PubMed ID: 30145235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevent shingles with Zostavax.
    Laustsen G; Neilson T
    Nurse Pract; 2007 Jun; 32(6):6-7. PubMed ID: 17557014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.